Two Years Of Growth Barely Change What You Pay For Intuitive Surgical

Consensus growth takes only a modest slice off the multiple, and the company has not yet set the instrument pricing that lands inside those two years.

Intuitive Surgical (ISRG) trades at about $401.23, roughly 32% below its 52-week high and down about 15% over the past twelve months while the S&P 500 returned 22%. A fall that size usually leaves a stock cheap. This one still costs about 37.7 times its last twelve months of adjusted earnings, and what happens to that number by 2027 turns on a price the company has not set.

Where The Multiple Actually Lands In 2027

Analysts expect about $12.08 a share by 2027, and on the earnings expected that year the multiple is only about 33.0 times. Two full years of forecast growth buy a 13% lower multiple. Some of that is basis, not earnings: the trailing figure sits on adjusted (non-GAAP) earnings while the forward figures sit on analyst consensus, and the two adjusted measures are not defined identically, so the two are not a like-for-like series.

Consensus Has Already Marked The Margin Down

The compound annual growth rate from trailing figures to those consensus estimates has earnings growing about 7.0% a year over the two years while revenue grows about 9.7%, and earnings rising more slowly than sales is the market penciling in some margin give-back. The forecast also assumes a slowdown: revenue of $11.03 billion over the trailing twelve months actually grew 20.7%, roughly double the pace now forecast. Management has guided the gross line higher for 2026, raising its non-GAAP gross profit margin guidance to a range of 68% to 69%. Profitability that holds up rather than gets traded away is one of the qualities the Trefis High Quality Portfolio insists on in its holdings.

The Instrument Price Intuitive Has Not Set Yet

Capital demand is not the issue. Da Vinci system placements rose 18% year over year in the second quarter of 2026, and the company credits the US gain to adoption of and upgrades to da Vinci 5. Recurring revenue, instruments included, made up 85% of that quarter’s total, so instrument pricing is not a detail. Beginning in the first half of 2027, the extended use program will increase the number of uses on a subset of its instruments, lowering customer cost per procedure to widen adoption in benign procedures. Intuitive has not finalized that pricing and says it will quantify the effect on its next earnings call, so the 2027 estimates sit in front of a number that does not yet exist.

What Being Right Is Worth, And What Being Wrong Has Cost

Analysts barely disagree about the earnings: the 17 covering 2027 put them between $11.85 and $12.70 a share. The argument is about the multiple, and there the arithmetic is thin. Midway between the 36.8 times on 2026 earnings and the 33.0 times floor is about 34.9 times the 2027 earnings, and at that multiple the stock is worth about $425, roughly 6% above today’s price. If the multiple drifts to the level those estimates already imply, the payoff is confirmation that today’s price was not an overpayment rather than a gain. The downside is not theoretical: in past market shocks Intuitive Surgical has fallen as much as 75% from peak to trough. For a holder the question is less whether the business works than whether a decline of this size is an entry point or just an early one.

When The Multiple Is The Risk

Nothing here says the systems stop selling. The point is narrower: your return rests on a re-rating nobody controls, landing on top of an instrument price the company has not set. Quality held to rules in a basket, rather than one concentrated position, is what the Trefis High Quality Portfolio is built to be. That portfolio has a track record of outpacing the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000.